Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
236 Clinical Updates found
MSK Chief of the Lymphoma Service Gilles Salles Presents Promising New Treatment for Patients with Diffuse Large B-Cell Lymphoma

Shape-Sensing Robotic-Assisted Bronchoscopy May Improve Diagnostic Efficiency, Shorten Time to Treatment for Patients with Malignant Lung Lesions

Updates 9/2/25: Dr. Bott, pathologist Marina Baine, MD, PhD, and interventional pulmonologist Or Kalchiem-Dekel, MD, recently led the first study to ev...
The timing and order of treatment modalities to address brain metastases is complex. MSK’s multidisciplinary brain metastasis experts create a customized treatment plan for each patient, ensuring multimodality treatments are delivered in the best order, as quickly as possible, for the greatest benefits.
Multimodality Care Is Improving Survival for Patients with Melanoma Brain Metastasis

Overall survival (OS) for patients with melanoma brain metastasis treated at Memorial Sloan Kettering Cancer Center has increased significantly over the past five years, up to 13 months, according to our research published recently in Cancer.
A Milestone for Precision Oncology: FDA Gives Green Light to MSK’s Genetic Database

OncoKB, a database developed and maintained by investigators at MSK, helps match patients with targeted therapies based on the mutations found in their tumors.
ASTRO 2021: New Study from Memorial Sloan Kettering Cancer Center Finds Targeted Radiation Beneficial in Cases of Advanced Lung Cancer

By C. Jillian Tsai, MD, PhD
Doctor and patient at MSK’s Multidisciplinary Brain Metastasis Clinic
Shorter time to stereotactic radiosurgery after brain metastases resection improves patient outcomes

Local control rates and overall survival (OS) were significantly higher for patients with brain metastases treated with adjuvant stereotactic radiosurgery (SRS) within two months of resection, compared to longer time intervals, according to our new study published recently in Neuro-Oncology Practice.
International Clinical Trial Delivers Promising Results of HER2-Targeted Therapy for Non-Small Cell Lung Cancer

By Bob Li, MD, PhD, MPH
Medical oncologist Alexander Drilon is Chief of MSK’s Early Drug Development Service. He specializes in lung cancer and early-phase clinical trials
Including AYA Patients in Cancer Clinical Trials

MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials.
Lead study author Andrea Cercek, MD, is Section Head, Colorectal Cancer and Co-Director of the Center for Young Onset Colorectal and Gastrointestinal at MSK
When Tailoring Cancer Treatment, Biology Matters More than Age

Early-onset colorectal cancer (CRC) is likely clinically and genomically indistinguishable from average-onset cancer, according to a recent study published in the Journal of the National Cancer Institute by MSK investigators.
Neurologist Dr. Adrienne Boire in her lab
Altered Mental Status in Cancer Patients after COVID-19 Driven by “Cytokine Storm” in CSF

MSK research team identifies unique markers of inflammation and neurodegeneration found in cerebrospinal fluid of cancer patients with altered mental status after initial SARS-CoV-2 infection, as likely cause of neurologic dysfunction.